LEIDEN, The Netherlands and SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company’s Supervisory Board.
Jaap Koopman, PhD, Chief Executive Officer, said: “We are very pleased to welcome Gilde Healthcare to our investor base and we appreciate the ongoing support and expertise that our investors can offer to our experienced team as we continue the development of ProFibrix. The proceeds of the financing will be applied to the ongoing clinical development of our lead product Fibrocaps(TM), and to the preclinical development of our pipeline products.”
Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant that rapidly stops bleeding after or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: it is ready for immediate use, is stable at room temperature, highly effective and fast acting. Fibrocaps is currently in a Phase II clinical trial in the Netherlands with results expected end of 2009.
Dirk Kersten, investment manager at Gilde Healthcare Partners, commented: “Gilde Healthcare Partners invests in biopharmaceutical companies with strong technology platforms and experienced management. We believe ProFibrix’ breakthrough fibrinogen technology is well-positioned to play an important role in the highly attractive hemostasis and regenerative medicine markets.”
ProFibrix expects to submit an Investigational New Drug Application (IND) for Fibrocaps to the U.S. Food and Drug Administration in the first half of 2010, and to conduct a combined phase II/III pivotal study in various surgical indications.
About ProFibrix
ProFibrix (www.ProFibrix.com) was founded in 2004 and is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA, USA The company leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field.
About Gilde Healthcare Partners
Gilde Healthcare Partners (www.gildehealthcare.nl) founded in 2000 is headquartered in Utrecht, the Netherlands with representatives in London and Madrid. Gilde Healthcare Partners has over EUR 275 million under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and enabling technologies. Gilde is a successful builder of healthcare businesses across Europe. By investing in companies with clear achievable business models, Gilde has used its financial resources and network to create significant value for both its investors and the entrepreneurs it backs. Companies that Gilde Healthcare Partners has proactively supported span all aspects of healthcare and include Ablynx (Belgium), Acacia Pharma (UK), Agendia (Netherlands), AMT (Netherlands), Ascendis Pharma (Denmark), Chroma Therapeutics (UK), Conatus (US), Flowcardia (US), Glycart (Switzerland), Santaris Pharma (Denmark) and Symphogen (Denmark). For a full list of Gilde’s portfolio companies please visit www.gildehealthcare.nl
About Index Ventures
Index Ventures is a leading pan-European venture capital firm dedicated to working with entrepreneurs who have the drive and ability to build world-class technology and life science companies. The Index Ventures team, which began investing in 1992, has a deep technology and scientific focus and the ability to leverage a network of cross-Atlantic strategic relationships. Index proactively seeks out the top entrepreneurial teams in each investment area and leverages its core assets in helping the entrepreneurs build their companies into global leaders. Index Ventures investors include leading technology firms and institutional investors. Previous investments include Addex Pharmaceuticals, Genmab, SGX Pharmaceuticals, Inc., Ingenium, ParAllele Bioscience, Molecular Partners and PanGenetics. Further information on Index Ventures can be found at www.indexventures.com
Source: ProFibrix B.V.
ProFibrix B.V., Jaap Koopman, Ph.D., CEO, Tel: + 31(0)6-21628475, E-mail:j.koopman at profibrix.com; ProFibrix Inc., Jan Ohrstrom MD, COO, Tel: + 1-2069105404, E-mail: j.ohrstrom at profibrix.com
Related Press Releases
Agendia Raises US $23 Million in Series E FinancingSeptember 21st, 2009 HUNTINGTON BEACH, California and AMSTERDAM -
- Company to Present at UBS Global Life Sciences Conference on Sept. 23
Agendia, a world leader in molecular cancer diagnostics, today announced the successful closing of a US $23 million series E investment.
AdvanDx Closes US$8 Million Financing Round and Elects New Board MemberAugust 17th, 2009 WOBURN, Massachusetts and VEDBAEK, Denmark -
- Financing provided by existing investors SLS Venture and LD Pensions
- Tina W. Christensen elected member of AdvanDx's Board of Directors
AdvanDx today announced it has closed another US$8 million in financing from existing stockholders, SLS Venture and LD Pensions.
Rayspan Raises US$12.5 million in Series B Financing from Khosla Ventures & Sequoia CapitalJuly 26th, 2009 SAN DIEGO -
Rayspan Corporation, the world's leading innovator of metamaterial air interface solutions for wireless communications, today announced that it has received US$12.5M in a Series B financing led by new investor Khosla Ventures, who was joined by existing Rayspan investor Sequoia Capital as well as individual private investors. The financing will be utilized by Rayspan to accelerate and expand the development and commercialization of its breakthrough metamaterial wireless technology.
Al Rajhi Bank Achieves SR 3.5 Billion in Profits During the First Half of This Year, a 5% Increase Over Last YearJuly 18th, 2009 RIYADH, Saudi Arabia - Al Rajhi Bank CEO, Mr. Abdullah Sulaiman Al Rajhi announced that the Bank posted a net profit of SR 3,503 million, compared to SR 3,344 million during the same period last year, representing a 5% increase.
ECE Braves the Crisis: Financing for 300-Million-Euro Project in Dortmund is SealedJuly 6th, 2009 DORTMUND and HAMBURG, Germany - Picture is available via EPA (European Pressphoto Agency) and can be downloaded free of charge at: www.presseportal.de/pm/64793/?live
The shopping gallery "Neues Thier-Areal" in the city of Dortmund ranks among Europe's largest privately financed projects being launched in the midst of the financial crisis. Just in time for the start of construction in July, ECE has secured the funding for the 300-million-Euro project in Dortmund.
ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)June 17th, 2009 SEATTLE, Washington, and LEIDEN, The Netherlands - ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate bleeding during liver surgery.
Tigo Energy Reaches Key Milestones and Raises US$10 Million 'B' Round FinancingMay 26th, 2009 LOS GATOS, California - Tigo Energy, (www.tigoenergy.com), the solar company whose unique technology significantly increases efficiency in photovoltaic solar installations, announced today that it has closed the second round of funding. The US$10 million round was led by ICV, and joined by all existing investors (Matrix Partners, OVP and Clal Energy).
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B FinancingMay 18th, 2009 DUBLIN - Completed Series B Total Stands at EUR21.3 m
DUBLIN, May 19 /PRNewswire/ --
Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced that Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3 million to the Series B financing announced in February this year, bringing the total round to EUR21.3 million. The new investors join Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba-Kernel in completing the round, which will enable Opsona to further expand its clinical development pipeline.
Cell Biosciences Closes US$10 Million Series C FinancingApril 8th, 2009 PALO ALTO, California - Cell Biosciences, a provider of nanoproteomic analysis systems to life science researchers, today announced the closing of a US$10 million Series C financing led by its largest shareholder, the Wellcome Trust. Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, Mitsui Ventures, Royal Bank of Canada and The Vertical Group also participated in the financing.
Al Rajhi Bank Presents Financing and Investment Opportunities at Riyadh Real Estate & Development ExhibitionApril 7th, 2009 RIYADH, Saudi Arabia - A Striking Pavilion That Awaits Visitors With Many Surprises
Al Rajhi Bank is taking part in the Riyadh Real Estate and Development Exhibition that is being held at the Riyadh International Exhibitions Center under the Patronage of HRH Prince Miteb bin Abdulaziz, Minister of Municipal and Rural Affairs. The Bank is presenting comprehensive real estate financing solutions and packages that offer unique features.
Related News
US Airways offering of 29 million shares raises $137.3 millionSeptember 30th, 2009 US Airways raises $137.3 million in stock offeringTEMPE, Ariz. — US Airways Group Inc.
AbitibiBowater needs debtor financing, bankruptcy court toldMay 2nd, 2009 AbitibiBowater needs debtor financingMONTREAL — Insolvent U.S. newsprint maker AbitibiBowater says it desperately needs a cash infusion from debtor financing after losing $2.2 billion last year.
Visteon attorney says company making good progress on bankruptcy financingJune 19th, 2009 Attorney says Visteon making progress on financingWILMINGTON, Del. — Auto-parts supplier Visteon Corp.
Optical equipment maker Oclaro raises outlook for its 1st-qtr revenue to $82M to $87MSeptember 21st, 2009 Oclaro raises outlook for its 1Q revenueSAN JOSE, Calif. — Oclaro Inc.
Janus says repurchase offer expires, raises cap to $444 millionAugust 12th, 2009 Janus says tender offer expires, raises offer capDENVER — Janus Capital Group Inc. on Wednesday said its offer to repurchase outstanding notes has expired and it has raised the repurchase amount after a better-than-expected response from investors.
CarMax renews, lowers warehouse facility for financing arm by $200MAugust 7th, 2009 CarMax renews, lowers warehouse facilityRICHMOND, Va. — Automotive retailer CarMax Inc.
Vehicle maker Oshkosh raises $358 million in public share offeringAugust 13th, 2009 Oshkosh raises $358 M in public share offeringOSHKOSH, Wis. — Vehicle maker Oshkosh Corp.
PCB set to earn whopping four million dollars from UAE seriesApril 10th, 2009 LAHORE - The Pakistan Cricket Board (PCB) is expecting to earn a massive four million dollars from the UAE one day international series against Australia. The board, which is facing a grim financial situation due to a series of tour cancellations, is expecting the forthcoming series to improve its bank account figures, as it has sold the title sponsorship rights to a Dubai builder for 440,000 dollars while co-sponsorship rights have been sold 225,000 dollars to a bank and 160,000 dollars to a cellular company.
Alliance One International plans an offering of $75 million senior notes due 2016August 12th, 2009 Leaf tobacco producer Alliance One offering notesMORRISVILLE, N.C. — Leaf tobacco producer Alliance One International Inc.
Ciber completes $155 million credit financing deal with multiple banksAugust 21st, 2009 Ciber completes credit financing dealGREENWOOD VILLAGE, Colo. — Ciber Inc., facing tougher terms on its borrowing, said Thursday it completed a 3-year, $155 million financing package led by Bank of America.
